The Debate Over Clopidogrel Continues

January 30, 2012
Genetics impacts how quickly people metabolize the commonly prescribed anti-clotting drug clopidogrel (Plavix), but whether genetics affects cardiovascular outcomes of people taking the drug is a subject of debate.
Read More

FDA Adds Boxed Warning to Plavix Label to Highlight Reduced Effectiveness of the Drug In Poor Metabolizers

March 15, 2010
The U.S. Food and Drug Administration (FDA) has updated the label information for the commonly used anti-clotting medication Plavix ® (clopidogrel) to stress to physicians that patients carrying certain genetic...
Read More

SNPwatch: Genetic Variants May Reduce Ability of Anti-Clotting Drug Clopidogrel to Prevent a Second Heart Attack

December 23, 2008
SNPwatch gives you the latest news about research linking various traits and conditions to individual genetic variations. These studies are exciting because they offer a glimpse into how genetics may...
Read More